Islet Sciences buys Diakine in diabetes merger
This article was originally published in Scrip
Executive Summary
Islet Sciences, which is developing products for insulin-dependent diabetes around its islet cell transplantation technology, is to acquire DiaKine Therapeutics in an all-share deal. DiaKine is developing novel immune modulators to treat diabetes and related conditions.